Literature DB >> 12215866

Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis.

J D Ringe1, H Faber, O Bock, S Valentine, D Felsenberg, M Pfeifer, H W Minne, S Schwalen.   

Abstract

Pain relief for patients with osteoporosis is important to maintain mobility and facilitate physical therapy. Transdermal fentanyl may be useful but has not been studied systematically. Patients with at least one osteoporotic vertebral fracture requiring strong opioids were enrolled and received transdermal fentanyl. Treatment history, pain, ease of physical therapy, and quality of life were recorded at baseline and after 4 weeks. Of 64 patients enrolled, 49 completed the study; 12 withdrew because of adverse events, most commonly nausea, vomiting, or dizziness. Pain at rest and on movement decreased significantly from baseline to final assessment (mean scores 7.84 and 8.55, respectively, at baseline, falling to 3.56 and 4.50 after 4 weeks). Quality of life improved significantly, and 61% of patients were satisfied with the treatment. Ability to undergo physical therapy improved significantly. Transdermal fentanyl is useful for the treatment of severe back pain caused by osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215866     DOI: 10.1007/s00296-002-0217-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis.

Authors:  Maria Papaleontiou; Charles R Henderson; Barbara J Turner; Alison A Moore; Yelena Olkhovskaya; Leslie Amanfo; M Carrington Reid
Journal:  J Am Geriatr Soc       Date:  2010-06-01       Impact factor: 5.562

2.  Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.

Authors:  T Armingeat; R Brondino; T Pham; V Legré; P Lafforgue
Journal:  Osteoporos Int       Date:  2006-08-08       Impact factor: 4.507

3.  Comparison of open-flow microperfusion and microdialysis methodologies when sampling topically applied fentanyl and benzoic acid in human dermis ex vivo.

Authors:  R Holmgaard; E Benfeldt; J B Nielsen; C Gatschelhofer; J A Sorensen; C Höfferer; M Bodenlenz; T R Pieber; F Sinner
Journal:  Pharm Res       Date:  2012-03-15       Impact factor: 4.200

Review 4.  Pharmacological options for pain control in patients with vertebral fragility fractures.

Authors:  Nuttan Kantilal Tanna; Terence Ong
Journal:  Osteoporos Sarcopenia       Date:  2022-10-03

5.  Long-term experiences of pain after a fragility fracture.

Authors:  A Gheorghita; F Webster; S Thielke; J E M Sale
Journal:  Osteoporos Int       Date:  2018-02-17       Impact factor: 4.507

6.  The impact of fentanyl matrix on pain and function in spinal disorder-related chronic pain: an open label trial in Korea.

Authors:  Jae Hyup Lee; Sung-Cheol Yun; Jung-Gil Lee; Kyoung Hyo Choi; Dong-Soo Kim; Kook-Jin Chung; Ye-Soo Park; Whan Eoh
Journal:  Asian Spine J       Date:  2011-05-02

7.  Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study.

Authors:  Xavier Le Loët; Karel Pavelka; Ute Richarz
Journal:  BMC Musculoskelet Disord       Date:  2005-06-15       Impact factor: 2.362

Review 8.  Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain.

Authors:  J Devulder; A Jacobs; U Richarz; H Wiggett
Journal:  Br J Anaesth       Date:  2009-09-06       Impact factor: 9.166

9.  Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

Authors:  Igor Kissin
Journal:  J Pain Res       Date:  2013-07-04       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.